Bayer Roundup Settlement: Who Qualifies and How Much Could They Get?
Also reported by BBC US, The Hill, Guardian World, PBS NewsHour
In today's quizSummary
A Missouri judge approved Bayer’s $7.25 billion settlement for lawsuits alleging that Roundup causes cancer. The program covers eligible U.S. residents exposed before February 17, 2026, who have or later receive a qualifying non-Hodgkin lymphoma diagnosis; payments depend on claim details and may be delayed by an appeal.Key Facts
- The settlement concerns lawsuits alleging a link between Roundup and non-Hodgkin lymphoma.
- Bayer denies liability, and Monsanto maintains that glyphosate does not cause cancer.
- Eligible claimants generally need medical proof of diagnosis, proof of U.S. residency and evidence of sufficient exposure.
- The program covers people diagnosed already or diagnosed before its 16-year coverage period ends; people who remain unaffected by then receive no payment and are released from the agreement.
- Standard award averages range from $10,000 to $165,000, with final payments potentially 20 percent above or below the applicable tier average.
- A separate quick-pay option offers qualifying residential claimants $6,000 to $14,500.
- Award calculations consider factors such as age, lymphoma type, exposure evidence, treatment intensity and cancer stage.
- An appeal could delay the settlement’s effective date and pause further payments into its fund.
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.